Indrayani Biotech Limited has issued a clarification to BSE Limited regarding recent share price movement following a surveillance inquiry. The company responded to BSE's communication dated April 8, 2026, providing detailed explanation for the observed price volatility in its scrip.

Recent Corporate Intimations Drive Market Activity

The company attributes the share price movement to market reaction following two significant intimations made on April 6, 2026:

Both meetings were scheduled to take place on April 9, 2026, the same date as the company's clarification to the exchange.

Regulatory Compliance and Disclosure

Indrayani Biotech emphasized its commitment to transparent disclosure practices under SEBI regulations. The company stated it has been consistently disclosing all material events, information, and announcements that may impact operations or performance, including price-sensitive information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

No Undisclosed Material Information

The company clarified that beyond the aforementioned disclosures, there is no undisclosed information or pending announcements that could influence price or volume behavior in the scrip. Management confirmed the share price movement is purely market-driven and emphasized that no material information remains undisclosed to the stock exchange.

Potential Business Restructuring

The Board Meeting scheduled for April 9, 2026, was specifically convened to discuss the proposal for a potential demerger of the company's food business into a separate entity. This strategic consideration represents a significant corporate development that could reshape the company's business structure and operations.

The clarification was signed by Ramya Ravi, Company Secretary and Compliance Officer, reaffirming the company's commitment to maintaining compliance with all listing regulations in letter and spirit.

Indrayani Biotech Limited has fulfilled its quarterly regulatory obligations by submitting the mandatory compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The submission demonstrates the company's adherence to securities market regulations governing dematerialization processes.

Regulatory Compliance Submission

The company submitted its Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 4, 2026. The certificate was addressed to both major depositories in India - National Securities Depository Limited and Central Depository Services (India) Limited. Company Secretary and Compliance Officer Ramya Ravi signed the submission letter on behalf of Indrayani Biotech Limited.

RTA Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, served as the Registrar and Transfer Agent for this compliance process. The RTA issued its confirmation certificate on April 3, 2026, one day prior to the company's submission to the depositories. Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited, signed the confirmation certificate.

Compliance Confirmations

The RTA certificate confirmed several critical compliance aspects for the quarter ended March 31, 2026:

• Securities received from depository participants for dematerialization were properly confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were confirmed or rejected within prescribed timelines
• Received security certificates were mutilated and cancelled after due verification by the depository participant
• Names of the depositories were substituted in the register of members as registered owners within prescribed timelines

Stakeholder Notifications

The company ensured comprehensive stakeholder communication by copying BSE Limited on the submission. The notification was sent to BSE's Department of Corporate Services at their Dalal Street, Mumbai office, maintaining transparency with the listing authority regarding the compliance certification process.

This quarterly submission represents standard regulatory practice for listed companies, ensuring proper oversight of dematerialization activities and maintaining investor confidence in the securities handling process.